SCIENTIFIC REPORTS

OPEN

Maternal serum cadmium level during pregnancy and its association with small for gestational age infants: a population-based birth cohort study

Received: 05 May 2015
Accepted: 19 February 2016
Published: 03 March 2016

Hua Wang^{1,2,*}, Lu Liu^{1,*}, Yong-Fang Hu¹, Jia-Hu Hao^{1,2}, Yuan-Hua Chen^{1,2}, Pu-Yu Su^{1,2}, Lin Fu¹, Zhen Yu¹, Gui-Bin Zhang¹, Lei Wang¹, Fang-Biao Tao^{1,2} & De-Xiang Xu^{1,2}

The association between maternal cadmium (Cd) exposure during pregnancy and the increased risk of fetal growth restriction (FGR) remains controversial. The present study evaluated the association between maternal serum Cd level and risk of small for gestational age (SGA) infants in a Chinese population. The present study analyzed a subsample of the C-ABCS cohort that recruited 3254 eligible mother-and-singleton-offspring pairs. Maternal serum Cd level during pregnancy was measured by graphite furnace atomic absorption spectrometry. The rate and odds ratio (OR) for SGA infant were calculated. The rate for SGA infant was 10.6% among subjects with H-Cd ($\geq 1.06 \mu\text{g/L}$), significantly higher than 7.5% among subjects with L-Cd ($< 1.06 \mu\text{g/L}$). OR was 1.45 (95% CI: 1.11, 1.90; $P = 0.007$) among subjects with H-Cd. Adjusted OR for SGA infants was 1.43 (95% CI: 1.09, 1.88; $P = 0.007$) among subjects with H-Cd. Taken together, we observe the fact that maternal Cd exposure at middle gestational stage, elevates the risk of SGA in contrast to early gestational stage. The present results might be interesting and worth more discussing, and guarantee to further studies.

Cadmium (Cd) is an important occupational and environmental toxicant. Workers in electroplating, pigments, paints, welding, and Ni-Cd batteries are usually exposed to a high level of Cd¹. As environmental Cd mainly distributed in soil, air and water, the general population is exposed to a low level of Cd via drinking water, food and cigarette smoking². Cd is a male reproductive toxicant in humans. Numerous epidemiological investigations showed that environmental Cd exposure was associated with male infertility and poor semen quality in humans^{3–7}. Cd is a testicular toxicant in rodent animals⁸. A lot of studies found that administration with a high dose of Cd induced germ cell apoptosis in mouse testes^{9–14}. As an environmental endocrine disruptor, Cd could inhibit the synthesis of testosterone (T) through down-regulating key genes for T synthesis in testis^{15,16}.

Increasing evidence demonstrates that Cd is an embryotoxic in rodent animals. Maternal Cd exposure during middle gestation induces fetal malformations in craniofacial region, limbs, trunk, viscera, and axial skeleton^{17–22}, while mid- and late-gestation exposure induces fetal growth restriction (FGR)^{16,23}. Nevertheless, the association between maternal Cd exposure during pregnancy and adverse outcomes in women remains to be investigated.

FGR, including small for gestational age (SGA) infants, increases the risks of infant morbidity and metabolic diseases in adulthood^{24,25}. The association between maternal Cd exposure during pregnancy and the increased risk of fetal growth restriction (FGR) remains controversial. An earlier report showed that fetal growth restriction is associated with higher placental Cd level²⁶. According to recent mother-child cohort studies, maternal blood Cd level during pregnancy was associated with lower birth weight and the increased incidence of SGA^{27,28}.

¹School of Public Health, Anhui Medical University; Hefei, China. ²Anhui Provincial Key Laboratory of Population Health & Aristogenics, Hefei, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to F.-B.T. (email: fbtiao@126.com) or D.-X.X. (email: xudex@126.com)

Parameters	Maternal serum cadmium level ^a		P-value
	L-Cd (<P ₇₅ , n = 2440)	H-Cd (≥P ₇₅ , n = 814)	
Maternal characteristics			
Age [y, n(%)]			
≤24	371 (15.2)	128 (15.7)	0.888
25–29	1540 (63.1)	515 (63.3)	
≥30	529 (21.7)	171 (21.0)	
Pre-pregnancy BMI [kg/m ² , n(%)]			
<18.5	515 (21.1)	180 (22.1)	0.762
18.5–24.9	1848 (75.7)	611 (75.1)	
≥25	77 (3.2)	23 (2.8)	
Monthly income [n(%)]			
Low income ^b	1114 (45.7)	372 (45.7)	0.147
Middle income ^b	976 (40.0)	346 (42.5)	
High income ^b	350 (14.3)	96 (11.8)	
Parity [n(%)]			
Primiparae	2372 (97.2)	68 (2.8)	0.673
Multiparae	789 (96.9)	25 (3.1)	
Time for collecting serum [n(%)]			
First trimester	845 (34.6)	277 (34.0)	0.754
Second trimester	1595 (65.4)	537 (66.0)	
Newborn characteristics			
Sex [n(%)]			
Male	1310 (53.7)	427 (52.5)	0.542
Female	1130 (46.3)	387 (47.5)	
Gestational age [wk, n(%)]			
<37	87 (3.6)	94 (11.5)	<0.001
≥37	2353 (96.4)	720 (88.5)	
Birth weight (g, mean ± SD)	3413 ± 443.8	3363 ± 510.6	0.013

Table 1. Characteristics of 3254 mothers and their newborns. ^aL-Cd for serum cadmium <1.06 µg/L, and H-Cd for serum cadmium ≥1.06 µg/L. ^bLow income for <2000 RMB (312 US dollars) per month; middle income for 2000–4000 RMB (312–624 US dollars) per month; high income for >4000 RMB (624 US dollars) per month.

Another prospective cohort study showed that maternal urinary Cd level during pregnancy was negatively associated with birth weight²⁹. These results are in disagreement with those from other studies, in which there was no significant association between maternal Cd exposure during pregnancy and birth weight^{30,31}. The present study mainly investigated the association between maternal serum Cd level during pregnancy and the risk of SGA infants in a large population-based birth cohort study. To explore the critical period for Cd-associated SGA, we further analyzed the association between maternal serum Cd level at different gestational stages and the risk of SGA infants in a Chinese population.

Results

All alcohol drinkers and cigarette smokers during pregnancy were excluded from this study. Total 3254 mother-and-singleton-offspring pairs were eligible for this study. The demographic characteristics of pregnant women, including mother's age, BMI before pregnancy, parity, and monthly income, were shown in Table 1. Total 1122 pregnant women (34.5%) were collected for serum in the first trimester and 2132 pregnant women (65.5%) were collected for serum in the second trimester. Median gestational age was 39 weeks (minimum: 31 weeks; maximum: 45 weeks). Among 3254 singleton infants, 82 were low birth weight infants and 336 were giant infants. In the present study, maternal serum Cd level was measured by graphite furnace atomic absorption spectrometry (GFAAS). The median serum Cd level was 0.79 µg/L (minimum: 0.04 µg/L; maximum: 8.08 µg/L). The 25th and 75th percentile was 0.57 and 1.06 µg/L. In addition, the distribution of maternal serum Cd levels during pregnancy and its association with birth weight were presented in Table 2. Total 601 (18.5%) pregnant women were for <0.50 µg/L, 2299 (70.7%) pregnant women for <1.00 µg/L, 2931 (90.1%) pregnant women for <1.50 µg/L. Interestingly, neonatal birth weight gradually decreased with the increase of maternal serum Cd level from 1.25 µg/L to more than 2.00 µg/L.

The association between maternal serum Cd level during pregnancy and fetal growth restriction was analyzed. As shown in Table 3, 7.5% newborns were with SGA infants among subjects with L-Cd. Interestingly, 10.6% newborns were with SGA infants among subjects with H-Cd (OR: 1.45; 95% CI: 1.11, 1.90; *P* = 0.007). After adjusting for pre-pregnancy BMI, maternal age, monthly income, gestational week for collecting serum, parity and gravidity, adjusted OR for SGA was 1.43 (95% CI: 1.09, 1.88; *P* = 0.009) among subjects with H-Cd using multiple logistic regression model (Table 3). According to a previous methods established by Kippler *et al.*, maternal serum

Serum Cd ($\mu\text{g/L}$)	n	Cumulative Percentage (%)	Birth Weight (g, 95%CI)
<0.25	140	4.3	3415.6 (3343.8, 3487.3)
0.25 – 0.49	461	18.5	3441.2 (3395.6, 3486.8)
0.50 – 0.74	872	45.3	3399.9 (3371.4, 3428.4)
0.75 – 0.99	826	70.7	3405.3 (3376.3, 3434.2)
1.00 – 1.24	418	83.5	3408.0 (3360.2, 3455.8)
1.25 – 1.49	214	90.1	3411.3 (3348.4, 3474.2)
1.50 – 1.74	139	94.3	3317.0 (3220.5, 3413.5)
1.75 – 1.99	145	98.8	3309.5 (3225.8, 3393.2)
≥ 2.00	39	100.0	3292.0 (3129.5, 3454.5)

Table 2. The distribution of maternal serum Cd levels during pregnancy and its association with birth weight.

	Maternal serum Cd level ^a		P-value
	Low (<P ₇₅)	High ($\geq$ P ₇₅)	
Number of live infants	2440	814	–
Number of SGA	184	86	–
Incidence (%)	7.5	10.6	0.007
Univariate OR (95%CI)	1.00	1.45 (1.11, 1.90)	0.007
Adjusted OR (95%CI) ^b	1.00	1.43 (1.09, 1.88)	0.009

Table 3. The incidence and odds ratio (OR) for SGA infants based on maternal serum Cd level during pregnancy. ^aLow for serum cadmium < 1.06 $\mu\text{g/L}$, and High for serum cadmium $\geq 1.06 \mu\text{g/L}$. ^bAdjusted for pre-pregnancy BMI, maternal age, time for collecting serum, monthly income, parity and gravidity.

	Maternal serum Cd level ^a		P-value
	Low (<P ₇₅)	High ($\geq$ P ₇₅)	
Number of live infants	845	277	–
Number of SGA	67	26	–
Incidence (%)	7.9	9.4	0.445
Univariate OR (95%CI)	1.0	1.20 (0.75, 1.93)	0.446
Adjusted OR (95%CI) ^b	1.0	1.21 (0.75, 1.96)	0.432

Table 4. The incidence and odds ratio (OR) for SGA infants based on maternal serum Cd level in the first trimester. ^aLow for serum cadmium < 1.06 $\mu\text{g/L}$, and High for serum cadmium $\geq 1.06 \mu\text{g/L}$. ^bAdjusted for pre-pregnancy BMI, maternal age, and monthly income, parity and gravidity.

Cd levels were classified as quartile 1 (Q1, <0.57 $\mu\text{g/L}$), quartile 2 (Q2, 0.57 to <0.79 $\mu\text{g/L}$), quartile 3 (Q3, 0.79 to <1.05 $\mu\text{g/L}$), and quartile 4 (Q4, $\geq 1.05 \mu\text{g/L}$) base on quartiles²⁹. As shown in Table S1, 10.6% newborns were with SGA infants among subjects with Q4 (OR: 1.51; 95% CI: 1.07, 2.14; $P = 0.020$), significantly higher than 7.3% among subjects with Q1.

The association between maternal serum Cd level at early gestational stage and fetal growth restriction was analyzed. As shown in Table 4, 7.9% newborns were with SGA infant among subjects with L-Cd at early gestational stage. In addition, 9.4% newborns were with SGA infant among subjects with H-Cd at early gestational stage (OR: 1.20; 95% CI: 0.75, 1.93; $P = 0.446$). After adjusting for pre-pregnancy BMI, maternal age, monthly income, parity and gravidity, adjusted OR for SGA was 1.21 (95% CI: 0.75, 1.96; $P = 0.432$) among subjects with H-Cd at early gestational stage (Table 4).

The association between maternal serum Cd level at middle gestational stage and fetal growth restriction was analyzed. As shown in Table 5, 7.3% newborns were with SGA infants among subjects with L-Cd at middle gestational stage. Of interest, 11.2% newborns were with SGA infants among subjects with H-Cd at middle gestational stage (OR: 1.59; 95% CI: 1.15, 2.21; $P = 0.006$). After adjusting for pre-pregnancy BMI, maternal age, monthly income, parity and gravidity, adjusted OR for SGA was 1.57 (95% CI: 1.13, 2.19; $P = 0.007$) among subjects with H-Cd at middle gestational stage (Table 5).

Discussion

Urinary Cd level is a good marker for Cd exposure²⁹, but blood Cd level is proposed as a more accurate estimator of the accumulated body burden^{32,33}. Although serum Cd level is only about 10% of blood Cd, it is well correlated with blood Cd level³⁴. The present study used serum Cd level rather than blood Cd level as a marker

	Maternal serum Cd level ^a		P-value
	Low (<P ₇₅)	High (≥P ₇₅)	
Number of live infants	1595	537	–
Number of SGA	117	60	–
Incidence (%)	7.3	11.2	0.005
Univariate OR (95%CI)	1.00	1.59 (1.15, 2.21)	0.006
Adjusted OR (95%CI) ^b	1.00	1.57 (1.13, 2.19)	0.007

Table 5. The incidence and odds ratio (OR) for SGA infants based on maternal serum Cd level in the second trimester. ^aLow for serum cadmium <1.06 µg/L, and High for serum cadmium ≥1.06 µg/L. ^bAdjusted for pre-pregnancy BMI, maternal age, and monthly income, parity and gravidity.

for environmental Cd exposure during pregnancy allowing us much greater flexibility in collecting, storing and transporting samples. Several studies analyzed serum Cd level among non-occupational population. An earlier report showed that mean serum level was 0.46 µg/L among non-smoking women³⁵. A report from Japan found that mean serum Cd level was 1.57 µg/L among women from a non-polluted area³⁶. According to a small case-control study, maternal serum Cd level during pregnancy was 2.22 µg/L among subjects delivered with babies with normal birth weight and 3.33 µg/L among subjects delivered with babies with low birth weight³⁷. A recent report from Korea showed that mean serum Cd level was 1.21 µg/L among non-occupational women³⁸. The present study analyzed serum Cd level among 3254 pregnant women. We showed that median of maternal serum Cd level was 0.787 µg/L (range: 0.044 to 8.077 µg/L). At middle gestational stage, the median serum Cd level was 0.794 µg/L (range: 0.044 to 8.077 µg/L). As cigarette smoking is an important risk factor for FGR^{39,40} as well as associated with the increased serum Cd level⁴¹, cigarette smokers during pregnancy were excluded from the present study.

A recent study showed that maternal urinary Cd level was negatively associated with birth weight²⁹. Another report from the EDEN mother-child cohort study found that maternal blood Cd level was negatively associated with birth weight in the offspring of women who smoked during pregnancy²⁸. According to a recent report from a North Carolina cohort, high maternal blood Cd level during pregnancy was associated with the increased risk of SGA infants²⁷. The present study analyzed the association between maternal serum Cd level during pregnancy and the risk of SGA infants among subjects in a Chinese population. We found that the incidence of SGA infants was 10.6% among subjects with H-Cd, significantly higher than 7.5% among subjects with L-Cd. The OR for SGA infants was 1.45 among subjects with H-Cd. After controlling for maternal age, pre-pregnancy BMI, monthly income, parity and gravidity, the adjusted OR for SGA infants was 1.43 among subjects with H-Cd. These results suggest that higher maternal serum Cd level during pregnancy was associated with the increased risk of SGA infants.

Several studies demonstrate that maternal Cd exposure at middle and late gestational stages induces FGR in mice^{16,21,42}. However, a Canadian birth study found that no association was observed between Cd level in maternal blood from the first and third trimesters and risk for SGA infants⁴³. Until now, no report analyzed the association between maternal Cd exposure at middle gestational stage and the risk of SGA infants. To investigate the critical period of Cd-associated SGA, the present study further compared the rate and OR of SGA infants among subjects with H-Cd at early and middle gestational stages. As expected, the rate of SGA infants was markedly increased among subjects with H-Cd at middle gestational stage. The OR was 1.59 among subjects with H-Cd at middle gestational stage. Unexpectedly, there was no significant difference on the rate of SGA infants between subjects with H-Cd at early gestational stage and subjects with L-Cd at early gestational stages. The OR was 1.20 ($P > 0.05$) among subjects with H-Cd at early gestational stage. These results suggest that maternal Cd exposure at middle gestational stage, but not early gestational stage, elevates the risk of SGA. The present results might be interesting and worth discussing, and guarantee to further studies.

The mechanism through which environmental Cd exposure during pregnancy results in FGR remains obscure. Two earlier studies observed the evidence of endoplasmic reticulum (ER) stress in human IUGR placentas^{44,45}. Data from animal experiments demonstrated that prolonged ER stress impaired not only placental development and morphogenesis but also placental transport and endocrine functions through down-regulating placental transporters and growth factors^{44,46}. Indeed, a report from our laboratory found that maternal Cd exposure at middle gestational stage induced placental ER stress and impaired placental and fetal development in mice²¹. Therefore, we guess that placental ER stress, which impairs placental development and function, may be one of the main mechanisms for Cd-induced FGR. Additional study is necessary to explore the exact mechanism through which Cd-induced ER stress mediates placental dysfunction and FGR.

In the present study, we focused on the association of maternal Cd exposure during pregnancy and the risks of SGA infants. However, this study has some limitations. First, the present study did not investigate the effects of maternal exposure to other heavy metals, such as lead and mercury, on fetal development. Second, the present study did not analyze the association between maternal serum Cd level and risk for other adverse pregnancy outcomes. Third, the Cd exposure levels from two groups of pregnant women are not repeat measurements. Additional work is required to determine whether environmental lead and mercury exposure during pregnancy elevates the risks of SGA infants. In addition, whether maternal Cd exposure during pregnancy induces low birth weight (LBW) and preterm birth needs to be clarified.

In summary, we observe the fact that maternal Cd exposure at middle gestational stage, elevates the risk of SGA in contrast to early gestational stage. The present results might be interesting and worth more discussing, and guarantee to further studies.

Methods

Study population. The China-Anhui Birth Cohort Study (C-ABCS) is a prospective population-based cohort study that recruited 16 766 pregnant women from six major cities of Anhui province in China between November 2008 and October 2010. Exclusion criteria were as follows: inability to provide informed consent, alcohol drinking and cigarette smoking during pregnancy, mental disorders, pregnancy-induced hypertension and preeclampsia, gestational diabetes, heart disease, thyroid-related disease, a history of ≥ 3 previous miscarriages, or plans to leave local places before delivery⁴⁷. The present study analyzed a subsample of the C-ABCS that recruited 4358 pregnant women from Hefei city of Anhui province from January 1 to December 31 in 2009. For this study, eligible participants were mother-and-singleton-offspring pairs in which serum samples from mothers were available for analysis of Cd level and offspring had a detailed birth records. Thirty-six pregnant women giving birth to twins, 15 fetal deaths, 2 stillbirths, 58 abortions and 589 withdrew were excluded from this study. In addition, 306 unavailable for maternal serum and 98 maternal serum collected at the third trimester were also excluded from this study. Total 3254 mother-and-singleton-offspring pairs were eligible for this study. All neonates were weighed at birth. The present study was approved by the ethics committee of Anhui Medical University. The methods were carried out in accordance with the approved guidelines. Oral and written consents were obtained from all pregnant women.

Definition of SGA. According to the Global Reference⁴⁸, we firstly calculated the average birth weight and standard deviation (SD) at 40 weeks of gestational age in the birth cohort. When the average birth weight and the coefficient of variation (12.31%, expressed as the percentage of SD to the mean birth weight) at 40 weeks of gestation for our population were entered into the Microsoft Office Excel Software in the webappendix 2, the programme generated the multiple reference percentiles of birth weight at 24 to 41 weeks of gestation (Table S2). A live-born infant with birth weight below 10th percentile for the gestational age was defined as SGA infants in the present study.

Measurement of serum Cd. Maternal fasting blood during pregnancy was collected in the morning. The blood samples were allowed to clot at room temperature for 30 min. Then maternal serum was obtained after centrifuging for 15 min at 3000 g. After discarding hemolytic specimens, available sera were stored at -80°C until analysis. To avoid contamination of exogenous Cd, all centrifuge tubes, storage vials and transfer pipettes were soaked for at least 24 hr in 10% HNO_3 at room temperature. Serum Cd concentration was determined by graphite furnace atomic absorption spectrometry (GFAAS; model: TAS-990; Purkinje General Instrument Co., Ltd, Beijing, China) coupled with a deuterium-lamp background correction system. All samples were prepared and analyzed according to a slightly modified method as previously described¹⁶. Serum samples were diluted with 1% HNO_3 according to 1:4 (v/v). Matrix modifiers colloid palladium (ColpdTM, Xinda Measuring & Control Technology Co., Ltd, Chengdu, China) were added to each standard, blank and sample dilution. The above-mentioned mixture was then detected using GFAAS. Each sample was analyzed in triplicate. Precision of the method was measured by coefficients of variation. Mean CV for measurement of serum Cd was 5.16% for within-day determinations and 6.55% for day-to-day determinations. The limit of detection was 0.01 $\mu\text{g/L}$. In this study, all subjects were divided into two groups according to maternal serum Cd level during pregnancy as previously described⁴⁹: low Cd group (L-Cd, $< 1.06 \mu\text{g/L}$) and high Cd group (H-Cd, $\geq 1.06 \mu\text{g/L}$) base on 75th percentile.

Confounding factors. According to a previous review⁵⁰, potential confounding factors that might influence the association between maternal Cd exposure during pregnancy and SGA infants were chosen as follows: maternal age (≤ 24 , 25–29 and ≥ 30 years), pre-pregnancy BMI (< 18.5 , 18.5 – 24.9 and $\geq 25 \text{ kg/m}^2$), average monthly income (Low income for < 2000 RMB or 312 US dollars per month; middle income for 2000–4000 RMB or 312–624 US dollars per month; high income for > 4000 RMB or 624 US dollars per month), time for collecting serum (first trimester: median 11 weeks of gestation, range 4–12 weeks of gestation; second trimester: median 16 weeks of gestation, range 13–27 weeks of gestation), and parity (primiparae and multiparae).

Statistical analysis. Proportions for maternal characters and neonatal characters in different serum Cd levels were provided. Differences between L-Cd group and H-Cd group were determined using chi-square tests. For adjustment of maternal age, pre-pregnancy BMI, monthly income, time for collecting serum and parity, Logistic regression model was used to estimate odds ratio (OR) and 95% confidence intervals (95% CI) for SGA infants. The forementioned results are referred to as relative risk (RR), because the OR is a good approximation of the risk ratio in the case of rare outcomes⁵¹. All statistical tests were two-sided using an alpha level of 0.05. We preformed all statistical analyses with statistical software SPSS (version 16.0).

References

1. Beveridge, R., Pintos, J., Parent, M. E., Asselin, J. & Siemiatycki, J. Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. *Am J Ind Med.* **53**, 476–485 (2010).
2. Honda, R. *et al.* Cadmium induced renal dysfunction among residents of rice farming area downstream from a zinc-mineralized belt in Thailand. *Toxicol Lett.* **198**, 26–32 (2010).
3. Xu, B., Chia, S. E., Tsakok, M. & Ong, C. N. Trace elements in blood and seminal plasma and their relationship to sperm quality. *Reprod Toxicol.* **7**, 613–618 (1993).
4. Telisman, S. *et al.* Semen quality and reproductive endocrine function in relation to biomarkers of lead, cadmium, zinc, and copper in men. *Environ Health Perspect.* **108**, 45–53 (2000).

5. Pant, N. *et al.* Lead and cadmium concentration in the seminal plasma of men in the general population: correlation with sperm quality. *Reprod Toxicol.* **17**, 447–450 (2003).
6. Xu, D. X. *et al.* The associations among semen quality, oxidative DNA damage in human spermatozoa and concentrations of cadmium, lead and selenium in seminal plasma. *Mutat Res.* **534**, 155–163 (2003).
7. Wu, H. M. *et al.* Cadmium level in seminal plasma may affect the pregnancy rate for patients undergoing infertility evaluation and treatment. *Reprod Toxicol.* **25**, 481–484 (2008).
8. Siu, E. R., Mruk, D. D., Porto, C. S. & Cheng, C. Y. Cadmium-induced testicular injury. *Toxicol Appl Pharmacol.* **238**, 240–249 (2009).
9. Ozawa, N. *et al.* Leydig cell-derived heme oxygenase-1 regulates apoptosis of premeiotic germ cells in response to stress. *J Clin Invest.* **109**, 457–467 (2002).
10. Kim, J. & Soh, J. Cadmium-induced apoptosis is mediated by the translocation of AIF to the nucleus in rat testes. *Toxicol Lett.* **188**, 45–51 (2009).
11. Ji, Y. L. *et al.* Crosstalk between endoplasmic reticulum stress and mitochondrial pathway mediates cadmium-induced germ cell apoptosis in testes. *Toxicol Sci.* **124**, 446–459 (2011).
12. Ji, Y. L. *et al.* Melatonin alleviates cadmium-induced cellular stress and germ cell apoptosis in testes. *J Pineal Res.* **52**, 71–79 (2012).
13. Ji, Y. L. *et al.* Ascorbic acid protects against cadmium-induced endoplasmic reticulum stress and germ cell apoptosis in testes. *Reprod Toxicol.* **34**, 357–363 (2012).
14. Ji, Y. L. *et al.* N-acetylcysteine protects against cadmium-induced germ cell apoptosis by inhibiting endoplasmic reticulum stress in testes. *Asian J Androl.* **15**, 290–296 (2013).
15. Ji, Y. L. *et al.* Pubertal cadmium exposure impairs testicular development and spermatogenesis via disrupting testicular testosterone synthesis in adult mice. *Reprod Toxicol.* **29**, 176–183 (2010).
16. Ji, Y. L. *et al.* Effects of maternal cadmium exposure during late pregnant period on testicular steroidogenesis in male offspring. *Toxicol Lett.* **205**, 69–78 (2011).
17. Hovland, D. N. Jr., Machado, A. F., Scott, W. J. Jr. & Collins, M. D. Differential sensitivity of the SWV and C57BL/6 mouse strains to the teratogenic action of single administrations of cadmium given throughout the period of anterior neuropore closure. *Teratology.* **60**, 13–21 (1999).
18. Scott, W. J., Jr., Schreiner, C. M., Goetz, J. A., Robbins, D. & Bell, S. M. Cadmium-induced postaxial forelimb ectrodactyly: association with altered sonic hedgehog signaling. *Reprod Toxicol.* **19**, 479–485 (2005).
19. Paniagua-Castro, N., Escalona-Cardoso, G. & Chamorro-Cevallos, G. Glycine reduces cadmium-induced teratogenic damage in mice. *Reprod Toxicol.* **23**, 92–97 (2007).
20. Robinson, J. F. *et al.* Cadmium-induced differential toxicogenomic response in resistant and sensitive mouse strains undergoing neurulation. *Toxicol Sci.* **107**, 206–219 (2009).
21. Wang, Z. *et al.* Cadmium-induced teratogenicity: association with ROS-mediated endoplasmic reticulum stress in placenta. *Toxicol Appl Pharmacol.* **259**, 236–247 (2012).
22. Veeriah, V. *et al.* Cadmium-induced embryopathy: nitric oxide rescues teratogenic effects of cadmium. *Toxicol Sci.* **144**, 90–104 (2015).
23. Ahokas, R. A., Dilts, P. V. Jr. & LaHaye, E. B. Cadmium-induced fetal growth retardation: protective effect of excess dietary zinc. *Am J Obstet Gynecol.* **136**, 216–221 (1980).
24. Saenger, P., Czernichow, P., Hughes, I. & Reiter, E. O. Small for gestational age: short stature and beyond. *Endocr Rev.* **28**, 219–251 (2007).
25. Bukowski, R. *et al.* Fetal growth and risk of stillbirth: a population-based case-control study. *PLoS Med.* **11**, e1001633 (2014).
26. Llanos, M. N. & Ronco, A. M. Fetal growth restriction is related to placental levels of cadmium, lead and arsenic but not with antioxidant activities. *Reprod Toxicol.* **27**, 88–92 (2009).
27. Johnston, J. E., Valentiner, E., Maxson, P., Miranda, M. L. & Fry, R. C. Maternal cadmium levels during pregnancy associated with lower birth weight in infants in a North Carolina cohort. *PLoS One.* **9**, e109661 (2014).
28. Menai, M. *et al.* Association between maternal blood cadmium during pregnancy and birth weight and the risk of fetal growth restriction: the EDEN mother-child cohort study. *Reprod Toxicol.* **34**, 622–627 (2012).
29. Kippler, M. *et al.* Maternal cadmium exposure during pregnancy and size at birth: a prospective cohort study. *Environ Health Perspect.* **120**, 284–289 (2012).
30. Zhang, Y. L. *et al.* Effect of environmental exposure to cadmium on pregnancy outcome and fetal growth: a study on healthy pregnant women in China. *J Environ Sci Health A Tox Hazard Subst Environ Eng.* **39**, 2507–2515 (2004).
31. Al-Saleh, I., Shinwari, N., Mashhour, A. & Rabah, A. Birth outcome measures and maternal exposure to heavy metals (lead, cadmium and mercury) in Saudi Arabian population. *Int J Hyg Environ Health.* **217**, 205–218 (2014).
32. Alfven, T., Jarup, L. & Elinder, C. G. Cadmium and lead in blood in relation to low bone mineral density and tubular proteinuria. *Environ Health Perspect.* **110**, 699–702 (2002).
33. Krieger, A. M. *et al.* Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. *Environ Health Perspect.* **114**, 113–119 (2006).
34. Lauwerys, R. R., Bernard, A. M., Roels, H. A. & Buchet, J. P. Cadmium: exposure markers as predictors of nephrotoxic effects. *Clin Chem.* **40**, 1391–1394 (1994).
35. Satarug, S., Nishijo, M., Ujjin, P., Vanavanitkun, Y. & Moore, M. R. Cadmium-induced nephropathy in the development of high blood pressure. *Toxicol Lett.* **157**, 57–68 (2005).
36. Osada, M., Izuno, T., Kobayashi, M. & Sugita, M. Relationship between environmental exposure to cadmium and bone metabolism in a non-polluted area of Japan. *Environ Health Prev Med.* **16**, 341–349 (2011).
37. Ikeh-Tawari, E. P., Anetor, J. I. & Charles-Davies, M. A. Cadmium level in pregnancy, influence on neonatal birth weight and possible amelioration by some essential trace elements. *Toxicol Int.* **20**, 108–112 (2013).
38. Kim, S. J., Han, S. W., Lee, D. J., Kim, K. M. & Joo, N. S. Higher Serum Heavy Metal May Be Related with Higher Serum gamma-Glutamyltransferase Concentration in Koreans: Analysis of the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-1, 2, 2010, 2011). *Korean J Fam Med.* **35**, 74–80 (2014).
39. Fantuzzi, G. *et al.* Exposure to active and passive smoking during pregnancy and severe small for gestational age at term. *J Matern Fetal Neonatal Med.* **21**, 643–647 (2008).
40. Baba, S., Wikstrom, A. K., Stephansson, O. & Cnattingius, S. Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. *BJOG.* **120**, 456–462 (2013).
41. Sorkun, H. C. *et al.* The effects of air pollution and smoking on placental cadmium, zinc concentration and metallothionein expression. *Toxicology.* **238**, 15–22 (2007).
42. Selvaratnam, J., Guan, H., Koropatnick, J. & Yang, K. Metallothionein-I- and -II-deficient mice display increased susceptibility to cadmium-induced fetal growth restriction. *Am J Physiol Endocrinol Metab.* **305**, E727–735 (2013).
43. Thomas, S. *et al.* Metals exposure and risk of small-for-gestational age birth in a Canadian birth cohort: The MIREC study. *Environ Res.* **140**, 430–439 (2015).
44. Yung, H. W. *et al.* Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. *Am J Pathol.* **173**, 451–462 (2008).

45. Lian, I. A. *et al.* Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. *Placenta*. **32**, 823–829 (2011).
46. Kawakami, T. *et al.* Prolonged endoplasmic reticulum stress alters placental morphology and causes low birth weight. *Toxicol Appl Pharmacol*. **275**, 134–144 (2014).
47. Tao, F. B. *et al.* Cohort Profile: the China-Anhui Birth Cohort Study. *Int J Epidemiol*. **42**, 709–721 (2013).
48. Mikolajczyk, R. T. *et al.* A global reference for fetal-weight and birthweight percentiles. *Lancet*. **377**, 1855–1861 (2011).
49. Al-Saleh, I., Shinwari, N., Mashhour, A., Mohamed Gel, D. & Rabah, A. Heavy metals (lead, cadmium and mercury) in maternal, cord blood and placenta of healthy women. *Int J Hyg Environ Health*. **214**, 79–101 (2011).
50. McCowan, L. & Horgan, R. P. Risk factors for small for gestational age infants. *Best Pract Res Clin Obstet Gynaecol*. **23**, 779–793 (2009).
51. Huybrechts, K. F. *et al.* Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*. **370**, 2397–2407 (2014).

Acknowledgements

We thank the Maternal and Child Care Service Centre of Hefei city, and all participants in the study. This study was partially supported by National Natural Science Foundation of China (81473016, 81172711, 81471467) and National Key Technology R & D Program (2006BAI05A03 to C-ABCS).

Author Contributions

The authors' responsibilities were as follows—D.X.X., F.B.T. and H.W. designed the research; L.L., H.W., L.W., G.B.Z., Y.F.H. and L.F. conducted the research; J.H.H. and P.Y.S. provided essential materials and subjects; H.W., L.L., Y.H.C. and Z.Y. analyzed data; D.X.X., H.W. and F.B.T. wrote the manuscript; D.X.X., F.B.T., H.W. and L.L. had primary responsibility for the final content of the manuscript; All authors: read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, H. *et al.* Maternal serum cadmium level during pregnancy and its association with small for gestational age infants: a population-based birth cohort study. *Sci. Rep.* **6**, 22631; doi: 10.1038/srep22631 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>